Prognostic factors and predictors of postoperative adjuvant transcatheter arterial chemoembolization benefit in patients with resected hepatocellular carcinoma

Table 4 Predictive factors for treatment response: Postoperative adjuvant transcatheter arterial chemoembolization vs surgery alone

	Events, n (%)		5-yr survival rate, %
Characteristic	PA-TACE	Surgery alone	PA-TACE	Surgery alone	HR(P/S)	95%CI	P value for interaction
Age (yr)							0.059
< 65	46 (29.3)	63 (39.6)	70.9	60.4	0.653	0.347-0.956
≥ 65	3 (9.7)	15 (50.0)	90.3	50.0	0.164	0.040-0.584
Gender							0.131
Male	43 (25.3)	63 (37.3)	74.7	62.7	0.598	0.406-0.882
Female	4 (21.1)	7 (35.0)	78.9	65.0	0.270	0.104-0.703
BMI							0.261
< 23	26 (31.0)	38 (46.9)	69.0	53.1	0.530	0.321-0.873
23-25	9 (15.8)	27 (44.3)	84.2	55.7	0.315	0.148-0.671
≥ 25	14 (29.2)	13 (27.7)	70.8	72.3	0.973	0.457-2.070
BCLC stage							0.236
0	3 (7.9)	12 (28.6)	92.1	71.4	0.256	0.072-0.909
A	46 (30.5)	66 (44.9)	69.5	55.1	0.570	0.391-0.830
HBV							0.274
Negative	5 (22.7)	6 (21.4)	77.3	78.6	0.988	0.302-3.247
Positive	44 (26.3)	72 (44.7)	73.7	55.3	0.493	0.339-0.717
HCV							0.527
Negative	49 (26.8)	77 (42.3)	73.2	57.7	0.560	0.376-0.770
Positive	0 (0)	0 (0)	100	100	-	-
Unknown	0 (0)	1 (20.0)	100	80.0	0.013	0.000-1357
Cirrhosis							0.943
No	17 (20.5)	26 (32.9)	79.5	67.1	0.550	0.298-1.013
Yes	32 (30.2)	52 (47.3)	69.8	52.7	0.535	0.345-0.832
Family History							0.793
No	43 (25.9)	69 (41.8)	74.1	58.2	0.528	0.360-0.772
Yes	6 (26.1)	9 (37.5)	73.9	62.5	0.612	0.218-1.721
MVI							0.048
No	37 (23.0)	66 (40.7)	77.0	59.3	0.469	0.313-0.701
Yes	12 (42.9)	12 (44.4)	57.1	55.6	0.911	0.605-1.708
AFP							0.984
≤ 200 ng/mL	22 (22.9)	36 (37.5)	77.1	62.5	0.529	0.311-0.898
> 200 ng/mL	27 (29.0)	42 (45.2)	71.0	54.8	0.533	0.328-0.865
ALBI grade							0.333
1	23 (22.1)	32 (29.6)	77.9	70.4	0.647	0.378-1.105
2	26 (30.6)	46 (56.8)	69.4	43.2	0.453	0.280-0.734
3	-	-	-	-	-	-
NLR							0.791
≤ Median	23 (26.7)	36 (42.4)	73.3	57.6	0.510	0.302-0.860
> Median	26 (25.2)	42 (40.3)	74.8	59.6	0.562	0.344-0.917
Ferritin							0.289
≤ 400 ng/mL	27 (21.6)	33 (26.6)	78.4	73.4	0.691	0.354-1.349
> 400 ng/mL	22 (34.4)	45 (69.2)	65.6	30.8	0.450	0.294-0.688
FHR							0.038
≤ Median	15 (15.3)	20 (20.6)	84.7	79.4	0.748	0.450-1.244
> Median	34 (37.4)	58 (63.0)	62.6	37.0	0.348	0.209-0.582
CRP							0.853
≤ 5 mg/L	38 (27.5)	60 (41.1)	72.5	58.9	0.556	0.370-0.835
> 5 mg/L	11 (21.6)	18 (41.9)	78.4	58.1	0.513	0.242-1.088

HR: Hazard ratio; P/S: Postoperative adjuvant transcatheter arterial chemoembolization to surgery alone; BMI: Body mass index; PA-TACE: Postoperative adjuvant transcatheter arterial chemoembolization; BCLC: Barcelona Clinic Liver Cancer system; HBV: Hepatitis B virus; HCV: Hepatitis C virus; MVI: Microscopic vascular invasion; AFP: Alpha fetoprotein; ALBI: Albumin-bilirubin; NLR: Neutrophil-to-lymphocyte ratio; FHR: Ferritin-to-hemoglobin ratio; CRP: C-reactive protein.